(Japan Daily Press) The Kameda Medical Center in Kamogawa City bought two systems worth $100,000, developed by Israeli company IceCure Medical Inc., to study their effectiveness in destroying cancerous lung tumors. The IceCure Medical system is based on the IceSense3, which was used to treat fibroadenoma breast tumors by injecting liquid nitrogen into the tumor. The system destroys the benign breast tumors without damaging the surrounding healthy tissues. The IceSense3 has already been approved in the U.S. and Europe.
2013-10-04 00:00:00Full ArticleBACK Visit the Daily Alert Archive